No Data
Historically the most 'competitive'? The Tenth Batch of National Procurement Pharmaceutical Catalog Is Officially Announced with one type having up to 31 companies competing.
①This afternoon, the National Pharmaceutical Joint Procurement Office officially announced the tenth batch of nationally purchased pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Several industry insiders have stated that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
livzon pharmaceutical group inc. (000513.SZ): has repurchased 1.00% of A-shares.
Gelonghui November 1st | livzon pharmaceutical group inc. (000513.SZ) announced that as of October 31, 2024, the company repurchased a total of 9,300,000 shares of the company's A shares through centralized auction trading, accounting for 1.00% of the total share capital of the company. The highest purchase price was RMB 37.45 per share, and the lowest price was RMB 32.95 per share. The total amount of funds used was RMB 330,114,122.82 (excluding transaction costs). The repurchase mentioned above complies with the company's established share repurchase program.
Livzon Pharmaceutical Group Inc. (000513.SZ): It is expected that several classic traditional Chinese medicine compound preparation products with in-process research will be successively listed for production in the next two years.
Livzon Pharmaceutical Group Inc. (000513.SZ) stated during a specific research conducted on October 31, 2024, that revenue from traditional Chinese medicine formulations in the first three quarters reached 1.041 billion yuan, a decrease of 16.49% year-on-year. The main reason for the revenue decline is the frequent flu outbreaks after the easing of COVID-19 restrictions last year, which led to strong sales of antiviral granules. This year, sales of this product have returned to normal, resulting in a significant decline compared to the same period last year. The company has laid out plans for new product development in the traditional Chinese medicine field, exploring multiple projects such as in-house formulations and classic prescriptions. In the long term, several classic traditional Chinese medicine compound formulations are expected to be released as part of the ongoing product research and development.
livzon pharmaceutical group inc. (000513.SZ): In the first three quarters, the revenue of hormone products reached 2.308 billion yuan, with a growth rate of 5.46%.
Gelonghui October 31st | Livzon Pharmaceutical Group Inc. (000513.SZ) stated during a specific target survey on October 31, 2024, that in the first three quarters, revenue from sex hormone products reached 2.308 billion yuan, with a growth rate of 5.46%. The key product, Liangbiruilin microspheres, as a hormonal regulatory drug, has high technological barriers and a good competitive landscape, with minimal policy impact. Currently, Liangbiruilin microspheres have passed consistency evaluation, and it is expected to maintain a differentiated competitive advantage in the near future.
livzon pharmaceutical group inc. (000513.SZ): Currently has deployed P-CAB products, and the Phase I clinical trial of tablet products has been completed.
Gelonghui October 31st丨Livzon Pharmaceutical Group Inc. (000513.SZ) stated when accepting a specific object investigation on October 31, 2024, that the company is continuously enriching the product portfolio of gastrointestinal products. Currently, P-CAB products have been laid out, and the phase I clinical trial of tablet products has been completed. An application has been submitted to the CDE for direct entry into phase III clinical trials without phase II. The injection form is also in simultaneous development.
Livzon Pharmaceutical Group's (SZSE:000513) Shareholders May Want To Dig Deeper Than Statutory Profit
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings YetNo Data
No Data
